Focal laser ablation provides a minimally invasive treatment that targets and ablates (destroys) only specific parts of glands, organs, or other tissue needing treatment, while preserving the surrounding and remaining tissue. This generally produces faster recovery, fewer side effects, and less pain and discomfort for patients that may not be good candidates or are inoperable for traditional open surgery*.
CLS is an innovative company within healthcare technology and therapy. With people in mind, we are at the forefront of developing more precise, more effective interventional healthcare solutions.
Our TRANBERG™ systems are approved and marketed in the US and Europe providing minimally invasive alternatives to traditional treatments.
Focal therapy using laser ablation is a growing treatment option for patients with prostate cancer. It is an effective method that treats the tumor locally, without damaging healthy tissue.
Patient Focused
Our driving force is to design and develop tools for treatment of severe diseases, such as cancer, in a precise and careful way. It is from this perspective we have developed the TRANBERG™ Thermal Therapy System for US Fusion-guided focal laser ablation.
Through research by our co-founder, professor Karl-Göran Tranberg, CLS has gained significant knowledge and experience with treating/killing cancer tumors using laser ablation under image guidance.
Today, our TRANBERG™ Thermal Therapy System is optimized for minimally invasive focal therapy of soft tissue and used to treat patients with localized prostate cancer.
At CLS we can look back on an exciting year where we have made significant progress towards our vision that laser ablation will be introduced as standard treatment in focal therapy and as an alternative to traditional surgery and, in the longer term, as a complementary systemic treatment of metastasized cancer.
The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.
Our CTO Cristina Pantaleone and VP Medical Affairs Hoda Tawfik, explain how the TRANBERG® Thermal Therapy Systems have been designed for precise and safe focal therapy of soft tissue, such as the prostate gland, and what kind of research CLS is now supporting.
*All the focal therapies report low rates of complications, and high rates of continence and erectile function preservation. Klotz et al. Curr Opin Urol. (2020).
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
Clinical Laserthermia Systems Americas Inc.
15707 Rockfield Blvd, Suite 130, Irvine
CA 92618 USA
Phone: +1 (949) 504-5440
E-mail: contact-us@clinicallaser.com
©Copyright 2022 CLS AB. All rights reserved.
MM-2022-026/Rev1